IRINOTECAN
Irinotecan is a topoisomerase I inhibitor used in cancer therapy. Side effects include severe diarrhea, neutropenia, and hair loss. Only GMP materials will be supplied, logistics all according to GDP.
About MedicaPharma
MedicaPharma distributes high-quality active pharmaceutical ingredients (APIs) to hospitals, commercial (compounding) pharmacies, research institutes, and universities worldwide.
Network of over +400 GMP API producers
Let us handle your sourcing / supply activities. Highly experienced in sourcing specialty raw pharmaceutical ingredients from niche GMP manufacturers around the world.
Why Choose MedicaPharma
Niche API specialist - Pro-active supply partner - High service level - Global network - Logistics according to GDP regulations
Product Description
Mechanism of Action
IRINOTECAN exhibits complex multipathway biochemical interactions involving receptorlevel modulation, regulatory enzyme interference, intracellular signalling adjustment and transcriptomic pathway influence. Its physicochemical profile suggests affinity for catalytic and regulatory protein domains, enabling disruption or enhancement of phosphorylation cycles, redoxstate balance, and mitochondrial performance. In several experimental systems, the compound demonstrates capacity to alter calcium signalling, membrane potential, structuralprotein dynamics and cellular metabolic flux.
Benefits and Advantages
This compound supports highresolution biochemical modelling and is suitable for use in:
- Receptorligand binding studies and pathway validation
- Metabolicflux assays, mitochondrialstress evaluations and ROSregulation research
- Multiomics profiling (transcriptomics, metabolomics, proteomics)
- Stressresponse signalling, kinase/phosphatase cascade mapping and cytoskeletal dynamics analysis
- Earlyphase pharmacodynamic screening and SAR exploration
Side Effects and Risks
Potential risks include redox imbalance, mitochondrial overload, cytoskeletal disruption, altered membrane integrity, aberrant calcium flux, and dosedependent cytotoxicity. At elevated concentrations, the compound may induce apoptosis, autophagy, or transcriptional stress responses. Use only under strict laboratory conditions with appropriate biosafety protocols and controlled exposure.
Only GMP materials will be supplied, logistics all according to GDP.
Datasheet
| Molecular Formula | C33H38N4O6 |
|---|---|
| Molecular Weight | 586.7 g/mol |
| CAS Number | 97682-44-5 |
| Storage Condition | Solutions of irinotecan hydrochloride prepared in 5% dextrose injection are physically and chemically stable for up to 24 hours when stored at room temperature (approximately 25 °C) under ambient fluorescent lighting or for up to 48 hours when protected from light and refrigerated at 2-8 °C. For irinotecan hydrochloride solutions prepared in 5% dextrose injection, the manufacturer recommends administration of such drug solutions within 24 hours if refrigerated or within 6 hours if maintained at room temperature because of the potential for microbial contamination during preparation of the admixtures. Solutions of irinotecan hydrochloride prepared in 0.9% sodium chloride are stable for up to 24 hours when stored at room temperature (approximately 25 °C) under ambient fluorescent lighting. The manufacturer states that solutions of irinotecan hydrochloride prepared in 0.9% sodium chloride may occasionally develop visible particulates when refrigerated at 2-8 °C; therefore, solutions prepared in sodium chloride injection should not be refrigerated but should be stored at room temperature and used within 6 hours. Freezing of commercially available irinotecan hydrochloride for injection concentrate or IV admixtures of the drug may result in formation of a precipitate and should be avoided. |
| Solubility | 1.07e-01 g/L |
| Purity | Purity information is available upon request (COA). |
| Synonym | irinotecan; 97682-44-5; (+)-Irinotecan; Irinophore C; Irinotecanum |
| IUPAC/Chemical Name | [(19S)-10,19-diethyl-19-hydroxy-14,18-dioxo-17-oxa-3,13-diazapentacyclo[11.8.0.02,11.04,9.015,20]henicosa-1(21),2,4(9),5,7,10,15(20)-heptaen-7-yl] 4-piperidin-1-ylpiperidine-1-carboxylate |
| InChl Key | UWKQSNNFCGGAFS-XIFFEERXSA-N |
| InChl Code | InChI=1S/C33H38N4O6/c1-3-22-23-16-21(43-32(40)36-14-10-20(11-15-36)35-12-6-5-7-13-35)8-9-27(23)34-29-24(22)18-37-28(29)17-26-25(30(37)38)19-42-31(39)33(26,41)4-2/h8-9,16-17,20,41H,3-7,10-15,18-19H2,1-2H3/t33-/m0/s1 |
| References |
3D Conformer.
(Click, turn or enlarge)
Download our GMP API Product List.
MedicaPharma is an EU-based supplier of GMP-certified APIs that serves leading healthcare institutions and research organizations.
Click here to download our full API product list.


